Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Interest Coverage Ratio (2016 - 2025)

Historic Interest Coverage Ratio for Protalix BioTherapeutics (PLX) over the last 13 years, with Q1 2025 value amounting to 690.83.

  • Protalix BioTherapeutics' Interest Coverage Ratio fell 544829.08% to 690.83 in Q1 2025 from the same period last year, while for Sep 2025 it was 135.47, marking a year-over-year increase of 284221.35%. This contributed to the annual value of 3.69 for FY2024, which is 1213.07% up from last year.
  • As of Q1 2025, Protalix BioTherapeutics' Interest Coverage Ratio stood at 690.83, which was down 544829.08% from 175.83 recorded in Q4 2024.
  • In the past 5 years, Protalix BioTherapeutics' Interest Coverage Ratio registered a high of 175.83 during Q4 2024, and its lowest value of 690.83 during Q1 2025.
  • Its 5-year average for Interest Coverage Ratio is 32.45, with a median of 4.1 in 2023.
  • In the last 5 years, Protalix BioTherapeutics' Interest Coverage Ratio skyrocketed by 252371.96% in 2024 and then plummeted by 544829.08% in 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Interest Coverage Ratio (Quarter) stood at 6.28 in 2021, then soared by 38.92% to 3.84 in 2022, then crashed by 89.0% to 7.25 in 2023, then surged by 2523.72% to 175.83 in 2024, then tumbled by 492.9% to 690.83 in 2025.
  • Its Interest Coverage Ratio was 690.83 in Q1 2025, compared to 175.83 in Q4 2024 and 15.35 in Q3 2024.